TNF and rheumatoid arthritis: In RA, an analysis from HeRBT for 1.028 patients treated with anti-TNFα agents (median follow up of 3 years for infliximab, etanercept and adalimumab) showed that more that 40% of patients with established RA had erosive disease, the median DAS28 was in the level of high disease activity and median HAQ was 1 at the time of starting an anti-TNFα biologic.7 At twelve months, the rates of DAS28 remission ranged between 15–23% and of low disease activity between 27–34%, with overall drug survival rates ranging between 64–68% at 1 year and 31%–49% at 5 years.